NICE reverses on Takeda drug after discount; Sandoz hit with $38M verdict in pricing case;

@FiercePharma: Quirky Medicaid rules gave generics firms a loophole to hike prices on capsules, but not tablets, whistleblower says. Report | Follow @FiercePharma

> Takeda Pharmaceutical's proposed discount on its bone cancer drug Mepact persuaded the U.K.'s cost effectiveness watchdog to recommend it for use by the National Health Service. Piece

> European regulators should require proposed drugs to be tested against existing treatments rather than placebo to make sure new meds add value, report says. Item

> Mississippi won a $38 million judgment against Sandoz, the generics unit of Novartis ($NVS), in an average wholesale pricing case. Report

> Merck ($MRK) was sued by three former employees who claim the company failed to pay their wages semi-monthly as required by West Virginia law. Report

> Sagent Pharmaceuticals got the FDA nod for its Haloperidol injection, a version of the schizophrenia drug Haldol. Article

> American Airlines Cargo has expanded its cold-chain service for pharma clients moving time- and temperature-sensitive drugs. Story

> New Zealand has rolled out a new national drug formulary encompassing clinical and reimbursement information. More

Biotech News

@FierceBiotech: Biomarkers vs. pen-and-paper tests for Alzheimer's: which wins? Story | Follow @FierceBiotech

@JohnCFierce: After a shakeup, iPierian names Nancy Stagliano, co-founder of CytomX, as new CEO. | Follow @JohnCFierce

@RyanMFierce: Researchers use neural #stem cells (of iPS variety) to study impacts of potential bipolar-disorder treatments. Article | Follow @RyanMFierce

> Fierce 15 f-star lands $708M antibody pact with Merck Serono. Piece

> Plexxikon's Hirth offers a "small" solution to Big Pharma's R&D woes. Story

> Eisai strikes creative deal to finance Ph3 cancer drug studies. News

Medical Device News

> St. Jude gets CE Mark for migraine device. News

> GI Dynamics starts trading on ASX. Report

> Veracyte thyroid test could reduce unnecessary procedures. More

> Urologix signs deal to sell Prostiva RF therapy system for BPH. Item

Drug Delivery News

> Virus sent on seek-and-destroy mission against cancer. Article

> Needle-free delivery market to double in 5 years, analyst says. Story

> Probiotics researcher says he's found a better delivery polymer. Article

> BDSI moves forward with anti-opioid drug, delivery method. Report

> Molecular motor could--someday--power drug delivery device. Piece

> Making sure your nanoparticles are pure. More

And Finally... Rich philanthropists aim to speed drug development for their children's debilitating diseases. Report

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.